EUVIMEDEUVIMED entdecken
Crossref

Wilms’ tumour and chemotherapeutic access

Sora Yasri

African Journal of Paediatric Surgery · 26.05.2026 · 12 (3) · 208

DOI: 10.67481/ajps.v12i3.679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift African Journal of Paediatric Surgery, online erschienen am 26.05.2026. Verfasst von Sora Yasri.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We enjoy reading the recent report on ‘Wilms’ tumour and chemotherapeutic access’.[1] Anyanwa et al. reported that ‘an institutionalised approach can help to improve access to anti-cancer drugs, reduce the rate of loss to follow-up and thus improve outcome’.[1] In fact, the problem of anticancer drug access can be seen in many developing countries. In a previous report by Uba and Chirdan, ‘poor availability of cytotoxic drugs’ is an important factor contributing to the poor outcome of disease in Nigeria.[2] It is suggested that pre-operative combined chemotherapy is required for the better operative curative outcome of paediatric cases of Wilms’ tumours.[3] To manage the high cost of chemotherapy, some new studies show that metronomic chemotherapy can be the hope for the management of the problem.

Zitieren

APA

Yasri, S. (2026). Wilms’ tumour and chemotherapeutic access. African Journal of Paediatric Surgery, 12(3), 208. https://doi.org/10.67481/ajps.v12i3.679

Vancouver

Yasri S. Wilms’ tumour and chemotherapeutic access. African Journal of Paediatric Surgery. 2026;12(3):208. doi:10.67481/ajps.v12i3.679

BibTeX
@article{Yasri2026,
  author = {Yasri, Sora},
  title = {Wilms’ tumour and chemotherapeutic access},
  journal = {African Journal of Paediatric Surgery},
  year = {2026},
  volume = {12},
  number = {3},
  pages = {208},
  doi = {10.67481/ajps.v12i3.679}
}
Kostenlos starten →